Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis

TOKYO, Sep 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent “Metoject Subcutaneous […]

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

TOKYO, Sep 27, 2021 – (JCN Newswire via SEAPRWire.com) – AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; […]

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”

TOKYO, Sep 13, 2021 – (JCN Newswire via SEAPRWire.com) – AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched “Humira Support Tool Ordering Service for Patients” an initiative intended to improve patients’ adherence to Humira therapy. “Humira Support Tool Ordering Service for Patients” is […]